KR20200031567A - 비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도 - Google Patents

비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도 Download PDF

Info

Publication number
KR20200031567A
KR20200031567A KR1020197037453A KR20197037453A KR20200031567A KR 20200031567 A KR20200031567 A KR 20200031567A KR 1020197037453 A KR1020197037453 A KR 1020197037453A KR 20197037453 A KR20197037453 A KR 20197037453A KR 20200031567 A KR20200031567 A KR 20200031567A
Authority
KR
South Korea
Prior art keywords
trypsin
disease
compound
animal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197037453A
Other languages
English (en)
Korean (ko)
Inventor
레자 파티
마크 레빗
테리 플라세
다니엘 아브람손
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20200031567A publication Critical patent/KR20200031567A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197037453A 2017-07-21 2018-07-13 비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도 Ceased KR20200031567A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762535376P 2017-07-21 2017-07-21
US62/535,376 2017-07-21
US201762574449P 2017-10-19 2017-10-19
US62/574,449 2017-10-19
US201762589734P 2017-11-22 2017-11-22
US62/589,734 2017-11-22
PCT/IB2018/000881 WO2019016595A1 (en) 2017-07-21 2018-07-13 USE OF WX-UK1 AND ITS PRODRANT WX-671 FOR THE TREATMENT OF NON-CANCER MEDICAL DISEASES

Publications (1)

Publication Number Publication Date
KR20200031567A true KR20200031567A (ko) 2020-03-24

Family

ID=65014605

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037453A Ceased KR20200031567A (ko) 2017-07-21 2018-07-13 비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도

Country Status (14)

Country Link
US (1) US20190022088A1 (https=)
EP (1) EP3654979A4 (https=)
JP (1) JP2020527582A (https=)
KR (1) KR20200031567A (https=)
CN (1) CN110785172A (https=)
AU (1) AU2018303799A1 (https=)
CA (1) CA3070037A1 (https=)
CL (1) CL2020000096A1 (https=)
IL (1) IL271878A (https=)
PH (1) PH12019502817A1 (https=)
RU (1) RU2020107706A (https=)
SG (1) SG11201912043QA (https=)
WO (1) WO2019016595A1 (https=)
ZA (1) ZA201908545B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494602B (zh) * 2020-04-14 2023-06-02 广州领晟医疗科技有限公司 一种治疗急性胰腺炎的组合物及其用途
CN111494392A (zh) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的组合物及其应用
CN113559100B (zh) * 2021-08-30 2023-01-17 广州领晟医疗科技有限公司 一种治疗肺损伤的组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534498A (en) * 1992-01-30 1996-07-09 Corvas International, Inc. Trypsin inhibitors
US7342018B2 (en) * 1998-07-20 2008-03-11 Wilex Ag Urokinase inhibitors and uses thereof
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
EP3309556B1 (en) * 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome

Also Published As

Publication number Publication date
SG11201912043QA (en) 2020-02-27
EP3654979A4 (en) 2021-04-14
RU2020107706A (ru) 2021-08-23
CN110785172A (zh) 2020-02-11
JP2020527582A (ja) 2020-09-10
CL2020000096A1 (es) 2020-08-28
PH12019502817A1 (en) 2020-09-14
CA3070037A1 (en) 2019-01-24
RU2020107706A3 (https=) 2021-10-15
US20190022088A1 (en) 2019-01-24
AU2018303799A1 (en) 2019-12-19
IL271878A (en) 2020-02-27
ZA201908545B (en) 2021-02-24
WO2019016595A1 (en) 2019-01-24
EP3654979A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
US10537561B2 (en) CSF-1R inhibitors for treatment of brain tumors
Stransky et al. The function of V-ATPases in cancer
JP2025122012A (ja) Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法
US20260085058A1 (en) Degraders of son of sevenless homolog 1
JP7301741B2 (ja) 補体活性のモジュレータ
TW200924739A (en) Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
JP2011518864A (ja) 血管新生の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ
ES2992827T3 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
US10336827B2 (en) Compositions and methods to treat solid tumors
KR20200031567A (ko) 비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도
JP2017528448A (ja) プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法
US20180335420A1 (en) Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis
US8501811B2 (en) TASPASE1 inhibitors and their uses
TWI804010B (zh) 作為血液學毒性生物標記之gdf-15
Xie et al. Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment
TW202140057A (zh) 環孢素類似物於治療癌症之用途
EP4661890A1 (en) Ptp1b/tc-ptp dual inhibitors and protein degraders
ES2919898B2 (es) Nuevo tratamiento del cáncer colorrectal
Wang et al. The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach
Ceccarelli et al. Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells
Xu et al. Macrophage TRIM21 Inhibition Ameliorates Murine Acute Pancreatitis via PHB2‐Mediated Mitochondrial Stabilization
JP5054529B2 (ja) フェニルアラニン誘導体の安定な投与形
ES2912350B9 (es) Nuevo tratamiento del cancer colorrectal
US10208028B1 (en) Methods of treating cancer
CN116889568A (zh) 一种抗肿瘤联合用药物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230801

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240201

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230801

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I